Showing results (1-10 of 57) with videos related to
Sort By:
Pageof 6
International Journal of Toxicology|March 3, 2006
Insulin glulisine--a comprehensive preclinical evaluationIngo Stammberger, Gerhard Seipke, Thomas BartelsDiabetes|August 28, 2003
A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1Irini Rakatzi, Stefanie Ramrath, Daniela Ledwig, et al.International Journal of Toxicology|January 5, 2012
Insulin glargine: a reevaluation of rodent carcinogenicity findingsIngo Stammberger, Luc EssermeantBiochemical and Biophysical Research Communications|October 11, 2003
[LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective actionIrini Rakatzi, Gerhard Seipke, Jürgen EckelInternational Journal of Toxicology|June 11, 2002
Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbitsThomas Hofmann, Georg Horstmann, Ingo StammbergerEuropean Endocrinology|April 11, 2018
Equivalent Recombinant Human Insulin Preparations and their Place in TherapyJuergen Sandow, Wolfgang Landgraf, Reinhard Becker, et al.Drugs|May 29, 2014
The evolution of insulin glargine and its continuing contribution to diabetes careRolf Hilgenfeld, Gerhard Seipke, Harald Berchtold, et al.International Journal of Toxicology|June 11, 2002
Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and miceIngo Stammberger, Axel Bube, Beate Durchfeld-Meyer, et al.Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution|September 2, 2003
Variations in the morphology, distribution, and arrangement of feathers in domesticated birdsThomas BartelsPlos One|March 9, 2010
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolitesMark R Sommerfeld, Günter Müller, Georg Tschank, et al.Pageof 6